BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stroehl YW, Letzen BS, van Breugel JM, Geschwind JF, Chapiro J. Intra-arterial therapies for liver cancer: assessing tumor response. Expert Rev Anticancer Ther 2017;17:119-27. [PMID: 27983883 DOI: 10.1080/14737140.2017.1273775] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Goehler A, Harry Hsu TM, Lacson R, Gujrathi I, Hashemi R, Chlebus G, Szolovits P, Khorasani R. Three-Dimensional Neural Network to Automatically Assess Liver Tumor Burden Change on Consecutive Liver MRIs. J Am Coll Radiol 2020;17:1475-84. [PMID: 32721409 DOI: 10.1016/j.jacr.2020.06.033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Doemel LA, Chapiro J, Laage Gaupp F, Savic LJ, Kucukkaya AS, Petukhova A, Tefera J, Zeevi T, Lin M, Schlachter T, Jaffe A, Strazzabosco M, Patel T, Stein SM. Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI. Eur Radiol 2021;31:2737-46. [PMID: 33123796 DOI: 10.1007/s00330-020-07381-9] [Reference Citation Analysis]
3 Young S, Taylor AJ, Sanghvi T. Post Locoregional Therapy Treatment Imaging in Hepatocellular Carcinoma Patients: A Literature-based Review. J Clin Transl Hepatol 2018;6:189-97. [PMID: 29951364 DOI: 10.14218/JCTH.2017.00059] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 2.8] [Reference Citation Analysis]
4 Ding J, Xiao H, Deng W, Liu F, Zhu R, Ha R. Feasibility of quantitative and volumetric enhancement measurement to assess tumor response in patients with breast cancer after early neoadjuvant chemotherapy. J Int Med Res 2021;49:300060521991017. [PMID: 33682494 DOI: 10.1177/0300060521991017] [Reference Citation Analysis]
5 Nezami N, VAN Breugel JMM, Konstantinidis M, Chapiro J, Savic LJ, Miszczuk MA, Rexha I, Lin M, Hong K, Georgiades C. Lipiodol Deposition and Washout in Primary and Metastatic Liver Tumors After Chemoembolization. In Vivo 2021;35:3261-70. [PMID: 34697157 DOI: 10.21873/invivo.12621] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Chen R, Kong W, Gan Y, Ge N, Chen Y, Ding H, Luo J, Wang W, Ren Z. Tumour stiffness associated with tumour response to conventional transarterial chemoembolisation for hepatocellular carcinoma: preliminary findings. Clin Radiol 2019;74:814.e1-7. [PMID: 31421865 DOI: 10.1016/j.crad.2019.07.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Rexha I, Laage-Gaupp F, Chapiro J, Miszczuk MA, van Breugel JMM, Lin M, Konstantinidis M, Duran R, Gebauer B, Georgiades C, Hong K, Nezami N. Role of 3D quantitative tumor analysis for predicting overall survival after conventional chemoembolization of intrahepatic cholangiocarcinoma. Sci Rep 2021;11:9337. [PMID: 33927226 DOI: 10.1038/s41598-021-88426-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Roddy H, Meyer T, Roddie C. Novel Cellular Therapies for Hepatocellular Carcinoma. Cancers (Basel) 2022;14:504. [PMID: 35158772 DOI: 10.3390/cancers14030504] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Zhang HF, Wang YC, Han YD. MicroRNA‑34a inhibits liver cancer cell growth by reprogramming glucose metabolism. Mol Med Rep 2018;17:4483-9. [PMID: 29328457 DOI: 10.3892/mmr.2018.8399] [Cited by in Crossref: 7] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]